FDA Approves Lilly’s Retevmo, the First and Only RET Inhibitor For Solid Tumor Indications
The FDA has approved Eli Lilly And Co’s (NYSE:LLY) Retevmo (selpercatinib, 40 mg & 80 mg capsules) for solid tumors. The…
Ensysce Biosciences Announces Initiation Of Second Human Abuse Potential Study, Being Conducted By Dr. Vince Clinical Research
~ Oral Opioid Abuse Being Explored for PF614 ~
~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~
SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce
Vir Biotechnology Announces First Patient Dosed In The Phase 2 SOLSTICE Trial Evaluating VIR-2218 And VIR-3434 For The Treatment Of Chronic Hepatitis D Virus Infection
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of
AstraZeneca Announced Lynparza Approved in China for Ovarian Cancer
AstraZeneca and MSD's Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive statu
FDA Approves Lilly’s Retevmo for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Eli Lilly and Company (NYSE: LLY) today announced the U.S.
Kinnate Biopharma Receives Fast Track Designation From The U.S. FDA For KIN-2787, An Investigational Pan-RAF Inhibitor
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug
Aetna Just Published A New Clinical Policy Bulletin Stating That Biogens Aduhelm Drug For The Treatment Of Alzheimer’s Disease Is Considered Medically Necessary
https://www.aetna.com/cpb/medical/data/900_999/0996.html
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
The FDA approved Fennec Pharmaceuticals Inc’s (NASDAQ:FENC) Pedmark to reduce the risk of chemo-induced ototoxicity in pediatric patients. Pedmark is indicated…
Some Medtronic’s Insulin Pumps Are Associated With Cybersecurity Risk, FDA Says
The FDA warned that certain types of Medtronic Inc’s (NYSE:MDT) MiniMed 600 Series insulin pump system were vulnerable to cyberattacks. Hackers could…
Cidara’s Lead Antifungal Candidate Goes Under Priority FDA Review
The FDA accepted Cidara Therapeutics Inc’s (NASDAQ:CDTX) marketing application seeking approval for rezafungin for candidemia and invasive candidiasis. Under the priority…